KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Research & Development (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Research & Development data on record, last reported at $84.8 million in Q4 2025.

  • For Q4 2025, Research & Development fell 15.86% year-over-year to $84.8 million; the TTM value through Dec 2025 reached $328.8 million, up 8.43%, while the annual FY2025 figure was $328.8 million, 8.43% up from the prior year.
  • Research & Development reached $84.8 million in Q4 2025 per ACAD's latest filing, down from $87.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $157.0 million in Q3 2023 and bottomed at $56.9 million in Q2 2021.
  • Average Research & Development over 5 years is $79.2 million, with a median of $75.7 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 126.17% in 2022, then plummeted 57.57% in 2024.
  • A 5-year view of Research & Development shows it stood at $66.9 million in 2021, then increased by 13.14% to $75.7 million in 2022, then fell by 11.88% to $66.7 million in 2023, then skyrocketed by 50.93% to $100.7 million in 2024, then dropped by 15.86% to $84.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $84.8 million in Q4 2025, $87.8 million in Q3 2025, and $78.0 million in Q2 2025.